Recent News

• 04.15.2025 - Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
• 04.15.2025 - Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
• 04.04.2025 - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 04.04.2025 - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 03.29.2025 - Effect of Plozasiran Targeting APOC3 on Lipoprotein Particle Number and Size Measured by NMR in Patients with Hypertriglyceridemia
• 03.29.2025 - Effect of Plozasiran Targeting APOC3 on Lipoprotein Particle Number and Size Measured by NMR in Patients with Hypertriglyceridemia
• 03.10.2025 - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
• 03.10.2025 - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
• 03.06.2025 - Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
• 03.06.2025 - Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Recent Filings

• 04.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - 144 Report of proposed sale of securities
• 04.10.2025 - 144 Report of proposed sale of securities
• 04.09.2025 - 144 Report of proposed sale of securities
• 03.19.2025 - 8-K Current report
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 424B7 Prospectus [Rule 424(b)(7)]
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 144 Report of proposed sale of securities